Leerink Partnrs Brokers Raise Earnings Estimates for Natera

Natera, Inc. (NASDAQ:NTRA) – Equities researchers at Leerink Partnrs boosted their FY2024 earnings per share estimates for Natera in a research note issued to investors on Wednesday, November 13th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of ($1.61) for the year, up from their previous estimate of ($1.83). The consensus estimate for Natera’s current full-year earnings is ($1.96) per share. Leerink Partnrs also issued estimates for Natera’s Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.40) EPS.

Natera (NASDAQ:NTRA) last posted its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The business had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. During the same quarter last year, the firm posted ($0.95) EPS. The company’s revenue for the quarter was up 63.9% on a year-over-year basis.

Other research analysts have also issued reports about the company. Leerink Partners boosted their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Morgan Stanley increased their price target on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday. Sanford C. Bernstein raised their price target on shares of Natera from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Canaccord Genuity Group boosted their price objective on shares of Natera from $150.00 to $165.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, TD Cowen raised their target price on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and an average price target of $137.65.

Natera Stock Down 3.3 %

Natera stock opened at $146.06 on Friday. The company has a quick ratio of 4.01, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The firm has a market cap of $19.28 billion, a P/E ratio of -82.99 and a beta of 1.53. The business has a fifty day moving average of $127.38 and a two-hundred day moving average of $115.61. Natera has a twelve month low of $52.01 and a twelve month high of $167.79.

Institutional Investors Weigh In On Natera

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Covestor Ltd lifted its holdings in shares of Natera by 34.3% in the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after buying an additional 95 shares during the period. GAMMA Investing LLC lifted its holdings in Natera by 32.7% in the third quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after acquiring an additional 106 shares during the period. CIBC Asset Management Inc lifted its holdings in Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock valued at $441,000 after acquiring an additional 111 shares during the period. RiverPark Advisors LLC boosted its position in Natera by 3.5% in the 3rd quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock worth $425,000 after purchasing an additional 112 shares in the last quarter. Finally, Moss Adams Wealth Advisors LLC grew its stake in shares of Natera by 5.4% during the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock worth $336,000 after purchasing an additional 135 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Gail Boxer Marcus sold 2,212 shares of the stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total value of $350,668.36. Following the sale, the director now owns 19,386 shares in the company, valued at $3,073,262.58. This represents a 10.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 4,728 shares of the firm’s stock in a transaction on Friday, November 15th. The stock was sold at an average price of $146.41, for a total transaction of $692,226.48. Following the transaction, the chief executive officer now directly owns 185,034 shares of the company’s stock, valued at approximately $27,090,827.94. This trade represents a 2.49 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 36,821 shares of company stock valued at $4,776,878 over the last quarter. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.